Extendicare (TSE:EXE – Get Free Report) had its price target increased by Desjardins from C$39.00 to C$39.50 in a research report issued to clients and investors on Monday, BayStreet reports. The firm currently has a “buy” rating on the stock. Desjardins‘s price target would indicate a potential upside of 40.32% from the stock’s current price. […]
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.